| PHARMACOLOGICAL STUDY |
|
| Year : 2019 | Volume
: 40
| Issue : 2 | Page : 127-133 |
|
|
Turmeric based oral rinse “HTOR-091516” ameliorates experimental oral mucositis
Suryakanth Dattatreya Anturlikar1, Mohammed Mukhram Azeemuddin1, Sandeep Varma1, Onkaramurthy Mallappa1, Dilip Niranjan1, Ashok Basti Krishnaiah1, Shruthi Manjunath Hegde1, Mohamed Rafiq1, Rangesh Paramesh2
1 Discovery Sciences Group, R and D Center, The Himalaya Drug Company, Bengaluru, Karnataka, India
2 R and D Center, The Himalaya Drug Company, Bengaluru, Karnataka, India
Correspondence Address:
Mohamed Rafiq
Discovery Sciences Group, R and D Center, The Himalaya Drug Company, Makali, Bengaluru - 562 162, Karnataka
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/ayu.AYU_282_18
|
|
|
Background: Prevalence and incidence of oral mucositis (OM) are rigorously increasing and there is no effective treatment. The herbal formulation “HTOR-091516” containing Curcuma longa, Triphala and honey were evaluated for the treatment of OM. Aim: The aim of this study was to evaluate the safety and efficacy of HTOR-091516, employing cellular model, human gingival fibroblasts-1 (HGF-1), and 5-fluorouracil (5-FU)-induced mucositis model in rats. Materials and Methods: The cell viability was assessed using 3-(4, 5-dimethylthiazolyl-2)-2, 5-diphenyltetrazolium bromide (MTT) assay and the inhibitory effect of HTOR-091516 on tumor necrosis factor-alpha (TNF-α) was evaluated using TNF-α bioassay in lipopolysaccharides-induced HGF-1. 5-FU and glacial acetic acid were used to induce OM in rats. Animals were divided into two groups, group 1 served as mucositis control and group 2 was treated with HTOR-091516 at the dose of 200 μl and TNF-α was estimated in plasma samples. Results: The in vitro safety of HTOR-091516 was evaluated in reconstructed human oral epidermis and was found to be nontoxic and exhibited concentration-dependent TNF-α inhibition in HGF-1. The treatment with HTOR-091516 reduced mucositis scores and mortality rate and also decreased the plasma TNF-α level. Conclusion: The present data indicate that HTOR-091516 is effective in the treatment of OM.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
